Compare

AddLife AB/Skr ALIF B

1D1W1M3M6MYTD1Y5YMAX

About AddLife AB

AddLife AB is a company active in the life sciences sector, providing products, services, and solutions primarily to healthcare and research facilities. Its operations are divided into two major segments: Labtech, which offers laboratory equipment, diagnostics, and consumables, and Medtech, which supplies medical devices and healthcare solutions. Founded in Sweden in 2015, AddLife operates across Europe with its headquarters in Stockholm. The company's strategic focus lies in leveraging its extensive network and expertise to cater to the specialized needs of its customers, supporting advances in life sciences and medical technology.
Ticker
Skr ALIF B
Sector
Health
Primary listing
XSTO
Employees
2,428
Headquarters
Stockholm, Sweden
Website
www.add.life

AddLife AB Metrics

BasicAdvanced
kr 22B
34.52
kr 5.27
1.52
kr 1.50
0.82%

What the Analysts think about AddLife AB

Analyst ratings (Buy, Hold, Sell) for AddLife AB stock.
Analyst projections of the future price of AddLife AB stock.

Bulls say / Bears say

Q3 sales rose 7%, including 4% organic growth, while adjusted EBITA increased 11% and its margin improved to 11.5% from 11.1%. That points to firmer operating momentum as well as sales growth. (AddLife)
AddLife completed three acquisitions in the first nine months and another after quarter-end, expected to add about SEK 350 million in annual sales. Management says the recent targets have margins above the group average, supporting a potential boost to growth and profitability. (MFN, AddLife)
Q3 operating cash flow rose 62% to SEK 236 million, while leverage stood at 2.5 times EBITDA, below AddLife’s 3.0-times ambition. That gives the group capacity to fund further growth without exceeding its stated leverage level. (AddLife, Investing.com)
Underlying growth remains moderate: organic sales growth was 4% in Q3 and across the first nine months, below the 7% reported Q3 sales increase. This leaves the business needing a stronger organic contribution to sustain faster expansion. (AddLife)
Performance is uneven across Medtech: its Q3 margin slipped to 11.3% from 11.6%, while a continuing healthcare dispute in Spain held back demand. A prolonged disruption could weigh on that segment’s recovery. (AddLife)
Valuation could limit upside: Affärsvärlden said the shares were not cheap in September, and DNB Carnegie cut its rating from Buy to Hold on 22 October even as it raised its price target. That points to less room for disappointment at the current price. (Affärsvärlden, MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.

AddLife AB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

AddLife AB Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing AddLife AB

Funds
Fund name
Fund size
Skr ALIF B weighting
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.12%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.12%
iShares MSCI World Small Cap€IUSN
$9B0.02%
iShares MSCI World Small Cap$WSML
$9B0.02%
iShares MSCI World Small Cap£WLDS
$9B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.